- Home
- DAIO vs BCAB Comparison
DAIO vs BCAB Comparison
Compare DAIO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAIO
- BCAB
- Stock Information
- Founded
- DAIO 1969
- BCAB 2007
- Country
- DAIO United States
- BCAB United States
- Employees
- DAIO N/A
- BCAB N/A
- Industry
- DAIO Electrical Products
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- DAIO Industrials
- BCAB Health Care
- Exchange
- DAIO Nasdaq
- BCAB Nasdaq
- Market Cap
- DAIO 22.0M
- BCAB 22.3M
- IPO Year
- DAIO N/A
- BCAB 2020
- Fundamental
- Price
- DAIO $3.09
- BCAB $0.38
- Analyst Decision
- DAIO Strong Buy
- BCAB Buy
- Analyst Count
- DAIO 1
- BCAB 2
- Target Price
- DAIO $4.00
- BCAB $1.00
- AVG Volume (30 Days)
- DAIO 39.1K
- BCAB 610.4K
- Earning Date
- DAIO 07-24-2025
- BCAB 08-07-2025
- Dividend Yield
- DAIO N/A
- BCAB N/A
- EPS Growth
- DAIO N/A
- BCAB N/A
- EPS
- DAIO N/A
- BCAB N/A
- Revenue
- DAIO $21,846,000.00
- BCAB $11,000,000.00
- Revenue This Year
- DAIO $7.06
- BCAB N/A
- Revenue Next Year
- DAIO $5.39
- BCAB N/A
- P/E Ratio
- DAIO N/A
- BCAB N/A
- Revenue Growth
- DAIO N/A
- BCAB N/A
- 52 Week Low
- DAIO $1.88
- BCAB $0.24
- 52 Week High
- DAIO $3.14
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- DAIO 67.05
- BCAB 41.17
- Support Level
- DAIO $2.70
- BCAB $0.38
- Resistance Level
- DAIO $3.11
- BCAB $0.46
- Average True Range (ATR)
- DAIO 0.12
- BCAB 0.05
- MACD
- DAIO 0.00
- BCAB -0.01
- Stochastic Oscillator
- DAIO 82.93
- BCAB 7.22
About DAIO Data I/O Corporation
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.